# Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

> **NCT03279861** · PHASE4 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Congestive Heart Failure
- Hypertension

## Interventions

- **DRUG:** Entresto
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT03279861
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11
- **Primary completion:** 2018-11
- **Final completion:** 2019-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** protocol change
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03279861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03279861, "Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03279861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*